Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials

    November 2025 in “ SKIN The Journal of Cutaneous Medicine ”
    Thierry Passeron, Lisa M. Arkin, Manabu Ohyama, Ruth Ann Vleugels, Maryanne M. Senna, Yves Dutronc, Stephanie C. Colvin, Tuhina Das, Angelina Sontag, Najwa Somani, Brittany G. Craiglow
    Image of study
    TLDR Baricitinib works better in adolescents than adults for treating severe alopecia areata.
    The study found that Baricitinib (Bari), a Janus kinase inhibitor, is effective and safe for treating severe alopecia areata (AA) in both adolescents and adults. In the BRAVE-AA trials, 257 adolescents and 1,200 adults were treated with either Bari 4mg, Bari 2mg, or a placebo. At 36 weeks, 42.4% of adolescents on Bari 4mg achieved a SALT score of less than 20, compared to 34% of adults. Adolescents showed higher response rates despite having more severe disease at baseline, indicating the potential benefits of early intervention. Common side effects included headache, acne, and upper respiratory tract infections.
    Discuss this study in the Community →